News from amgen inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 16, 2015, 16:05 ET
Amgen Logo.

Amgen Announces Webcast Of 2015 First Quarter Financial Results

 Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 21, 2015, after the close of...

Apr 15, 2015, 17:04 ET
General Amgen Logo

FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure

 Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Corlanor® (ivabradine), an...

Apr 06, 2015, 05:00 ET
Amgen Logo.

European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer

Amgen (NASDAQ: AMGN) today announced that the European Commission approved a new use of Vectibix® (panitumumab) as first-line treatment in...

Mar 30, 2015, 16:07 ET
Amgen Logo.

Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference

 Amgen (NASDAQ: AMGN) will present at the Goldman Sachs Key Debates in Biosimilars conference at 9:05 a.m. ET on Thursday, April 2, 2015, at...

Mar 30, 2015, 09:00 ET
Amgen Logo.

FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of...

Mar 26, 2015, 16:01 ET
Amgen Breakaway from Cancer Logo.

Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins Nationwide Search For Ten Champions In The Fight Against Cancer

Amgen (NASDAQ:AMGN) today announced that breast cancer survivor Joan Lunden has been named 2015 Honorary Breakaway from Cancer® Champion...

Mar 23, 2015, 09:00 ET
Amgen Logo.

Amgen To Webcast Investor Call At the 73rd Annual Meeting of the American Academy of Dermatology

 Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 73rd Annual Meeting of the American Academy of Dermatology...

Mar 20, 2015, 09:00 ET
Amgen Logo.

Amgen Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha™ (evolocumab) In Japan

Amgen (NASDAQ: AMGN) today announced that an application seeking marketing approval of RepathaTM (evolocumab) for the treatment of high cholesterol...

Mar 17, 2015, 16:01 ET
Amgen Logo.

Amgen To Present 10 Abstracts From Its Dermatology Portfolio At The 73rd Annual Meeting Of The American Academy Of Dermatology

Amgen (NASDAQ:AMGN) today announced that it will present data from multiple brodalumab and Enbrel® (etanercept) studies at the 73rd Annual...

Mar 15, 2015, 11:00 ET
Amgen Logo

Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine

 Amgen (NASDAQ: AMGN) today announced one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2...

Mar 14, 2015, 12:30 ET
Mar 04, 2015, 16:30 ET
Amgen Logo.

Amgen Announces 2015 Second Quarter Dividend

Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.79 per share dividend for the second quarter of 2015. The dividend...

Mar 02, 2015, 16:30 ET
Amgen Logo.

Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data

Amgen (NASDAQ:AMGN) today announced that it will present 15 abstracts, including data evaluating RepathaTM (evolocumab), an investigational...

Mar 02, 2015, 16:01 ET
The Neulasta(R) Delivery Kit with the On-body Injector for Neulasta

Amgen Announces Launch Of New Neulasta® (Pegfilgrastim) Delivery Kit

 Amgen (NASDAQ: AMGN) today announced that the Neulasta® (pegfilgrastim) Delivery Kit is now available in the United States (U.S.). The...

Mar 01, 2015, 19:00 ET
Kyprolis(r) (carfilzomib) Product Image

Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

 Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced the results from a planned interim analysis showing that...

Feb 27, 2015, 09:00 ET
Amgen Logo

Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer

 Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...

Feb 26, 2015, 16:05 ET
Amgen Logo.

Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma

Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has accepted the...

Feb 25, 2015, 16:44 ET
Amgen Logo.

Amgen Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

Amgen (NASDAQ: AMGN) today announced results from the head-to-head Phase 3 study comparing AMG 416 with cinacalcet for the treatment of secondary...

Feb 25, 2015, 16:04 ET
Amgen Logo.

Amgen To Present At The Cowen And Company 35th Annual Health Care Conference

Amgen (NASDAQ: AMGN) will present at the Cowen and Company 35th Annual Health Care Conference at 2:50 p.m. ET on Monday, March 2, 2015, at the...

Feb 11, 2015, 16:22 ET
Amgen Logo.

Amgen Announces FDA Advisory Committees To Review Talimogene Laherparepvec For The Treatment Of Patients With Metastatic Melanoma

 Amgen (NASDAQ: AMGN) announced today that the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory...